Everybody already knows this stock for one thing, and that is the whole opportunity.

Say the name Eli Lilly, ticker LLY, and people picture one thing. Weight-loss drugs. The shots everybody is talking about, the obesity boom, the reason the stock went vertical over the last couple of years. That label is not wrong.

It is just badly out of date, and the traders still trading it as a one-trick pharma name are about to miss the second act.

Here is what has been happening while everyone kept calling it a weight-loss stock.

Lilly has been taking the mountain of cash those drugs generate and quietly building one of the most aggressive artificial intelligence operations in the industry.

Not a press release containing the letters A and I. Real infrastructure, real money, real partners.

Start with Nvidia.

In January, the two of them announced a co-innovation AI lab and committed up to $1 billion over five years to build it.

On top of that, Lilly is constructing what it calls the most powerful AI supercomputer in the pharmaceutical industry, an “AI factory” pointed straight at discovering new drugs faster than any human team could.

Then, in March, they signed a deal worth up to $2.75 billion with an AI drug developer called Insilico, paying part of it upfront and the rest as the drugs hit milestones.

The CEO even described their new AI platform as an “App Store” for biotech scientists, renting out machine-learning models trained on decades of Lilly’s own research.

That is not a weight-loss company.

That is a company using its weight-loss money to buy its way to the front of the AI-in-medicine race, and most people have not repriced a dime of it.

The market has not caught up to that story yet. The chart says it is starting to.

Look at where LLY trades. It closed at $1,117, climbing hard off its May low and pressing right back up toward its highs near $1,135.

That is not a stock drifting. That is a stock the buyers have taken back control of, and they are doing it with conviction.

Now, the moving averages, which is one reason it gets me to write about this. The 8-day average is on top, the 21-day sits right under it, the 34-day under that, all three rising, with price living above the entire stack.

When they line up in that order, every buyer from last week, last month, and back in the spring is sitting green at the same time. Nobody is trapped overhead waiting to dump shares into the next pop. The path up is clear.

Then there is the squeeze, and on LLY it is on right now.

A squeeze is what happens when a stock that has been moving suddenly goes quiet.

The daily range tightens, the candles shrink, and the energy does not leave, it just builds up with nowhere to go yet.

The chart flags it for you with a row of red dots that read squeeze on, while the momentum underneath it starts ticking higher. And this one is coiling up near the highs, which is the strongest place for it to wind up, not down in the gutter after a beating.

The timing is the last piece.

Lilly reports earnings on August 5. So you have a stock the market still misreads, already trending hard, stacked on the daily, winding up tight, walking right into the kind of event that tends to set these coils loose.

Your Action Plan

I would not be shocked to see LLY make a real move as that August earnings date gets closer, and I will be stalking it for a swing if it gives me the trigger.

That is the slower side of how I trade. The other side is where it gets fun.

My Fast Cash trades are the quick strikes, in and out in minutes instead of weeks, risk locked down tight before I ever click buy, and never by betting on some stock that is falling apart.

I already have the next one loaded and ready to fire before the week is out. If that pace is more your speed, here is where you can ride along on Fast Cash.